Episode #3: Experience with Jelmyto

Endourological Society September 2021
In Episode 3, experts discuss the utility of antegrade instillation of Jelmyto as a viable option, which may reduce adverse effects associated with repeated instrumentation of the ureter. The urologist should be cognizant of tumor location, as this may impact placement of the nephrostomy tube and subsequent efficacy of treatment. Episode #3 delves into these treatment considerations.

Episode #1: Temperature Management Matters: Past, Present and Future

Endourological Society September 2021
The Podcast entitled “Temperature Management Matters: Past, Present and Future” with Dr. Nickolas Johnson, Associate Professor, University of Washington focused on lessons learned from past clinical trials in cardiac arrest and next steps for improving TTM protocols. In addition to reviewing published results from the completed TTM1 and TTM2 trials, Dr. Johnson discussed the new ICECAP trial that will use an innovative adaptive randomization approach to clarify the optimal duration of cooling associated with best outcomes in post cardiac patients. Consistent with the concept of specialized medicine, these types of clinical studies and resulting data could result in new guidelines for the use of temperature management protocols in terms of cooling duration in this heterogenous population of patients.

Episode #41: Dual Lumen URS

Endourological Society September 2021
In episode forty-one, Dual Lumen URS, Dr. Jaime Landman shares his experience with the Wolf Dual Lumen Cobra flexible Ureteroscope and some insights on disposable technology.

Episode #2: Meeting the Unmet Need in LG IR-NMIBC

Endourological Society September 2021
In Episode 2, doctors examine how effectively managing both low and intermediate risk NMIBC continues to evolve. Given both the global BCG shortage as well as the unmet need for more effective therapies, innovative strategies and trials are required to enhance our patient’s clinical outcomes as well as to decrease the well described morbidity and costs associated with current NMIBC therapies.